Trial for James Mazzo Ends in Hung Jury; Co-defendants DeCinces, Parker Convicted

May 12, 2017: By Joan McKenna

A federal jury concluded May 12 that it could not reach a verdict in the US government’s case against ophthalmic industry veteran James Mazzo on charges of insider trading, but jury members convicted co-defendants Doug DeCinces on 13 counts and David Parker on three counts.

Jury members deliberated for seven days.

Jury members deliberated seven days.

The jury told US District Judge Andrew Guilford on Day 7 of deliberations that members couldn’t reach agreement on the counts against Mazzo. Guilford declared a mistrial in his case.

Guilford will hold a status conference June 12 to discuss future proceedings in the case, including sentencing hearings.

Mazzo, 60, the former CEO and chairman of Advanced Medical Optics (AMO), was accused of providing nonpublic information to friend and neighbor DeCinces, a former major league ballplayer, in advance of Abbott’s 2009 acquisition of AMO. DeCinces made a profit of $1.3 million trading on the information, and he passed the information to associates, who also benefited, federal prosecutors said. The government also alleged that Mazzo shared inside information with DeCinces in relation to AMO’s 2007 acquisition of IntraLase Corp.

Jury members were asked to decide whether the US government’s case—which linked trades by DeCinces to prior phone calls or outings involving Mazzo and DeCinces—was sufficient for a conviction without evidence of what was said during those exchanges.

During closing arguments, defense attorneys spent five hours trying to convince the jury that prosecutors had produced no real evidence, while federal prosecutor spent one hour insisting that the evidence was overwhelming, according to Courthouse News Service.

The trial, which began March 7, was held in the US District Court for the Central District of California.

Four weeks into the trial, Mazzo’s lawyers filed a motion for acquittal, claiming: “Putting aside the government’s rhetoric, there is no link between Mr. Mazzo and the trades in this case. Instead of relying on concrete evidence, the government piles unsupported inference upon unsupported inference, hoping that speculation will suffice in this criminal case. The government’s case rests on a series of unsupported assumptions: because Mr. Mazzo and Mr. DeCinces were friends and talked on occasion, Mr. Mazzo must have told Mr. DeCinces material, nonpublic information about the AMO-Abbott transaction; because Mr. DeCinces traded in AMO stock, he must have relied on inside information; because Mr. DeCinces was enthusiastic about the stock in early January, he must have known exactly what was going on within AMO. None of these inferences are supported by evidence, and none would convince a rational juror of guilt beyond a reasonable doubt.”

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022